INTRODUCTION
============

It is well known that the liver plays an important role in lipogenesis, gluconeogenesis, and cholesterol metabolism ([@ref24]). Over the last decade, it has been shown that metabolic syndrome and obesity promote pathophysiological changes that can cause liver damage and ultimately lead to liver disease, such as non-alcoholic fatty liver disease (NAFLD), the most common liver disease in Western societies ([@ref7]). Lipid accumulation and oxidation of fatty acids play an important role in damage, repair, and regeneration of the liver due to autosomal induction and production of reactive oxygen species (ROS) ([@ref7]). Dyslipidemia is prevalent amongst people with NAFLD and has an important role in the development of cardiovascular disease, which is the leading cause of mortality for these patients ([@ref28]). Dyslipidemia in patients with NAFLD is typically characterized by increased levels of low-density lipoproteins (LDL) and hypertriglyceridemia, and decreased levels of high-density lipoproteins (HDL) ([@ref28]). Furthermore, it has been shown that treatment with interferon alpha (IFNα) in combination with ribavirin in patients infected with hepatitis C virus influences lipid metabolism ([@ref19]). These therapies reduce serum HDL levels and increase triglyceride (TG) levels and, consequently, the amount of fat in the liver ([@ref23]).

Exercise and diet are the first-line approaches for managing dyslipidemia ([@ref3]). When these approaches are insufficient, the first-line pharmacologic approach for managing dyslipidemia is treatment with statins, which have proven effectiveness in preventing primary and secondary cardiovascular disease ([@ref29]; [@ref4]). Moreover, a large number of studies have shown that L-carnitine supplementation is effective for normalizing the blood concentrations of cholesterol and TGs ([@ref21]; [@ref1]). A systematic review and meta-analysis indicated that L-carnitine supplementation can significantly decrease LDL concentrations, whereas, it does not significantly affect concentrations of total cholesterol (TC), HDL, and serum TG in patients requiring hemodialysis ([@ref12]). However, a recent meta-analysis, which included a trials conducted on adults with cardiovascular risk factors, demonstrated that L-carnitine supplementation significantly reduces concentrations of TC, LDL, and HDL but does not significant effect concentrations of TG ([@ref5]). Due to the contradictory results found in the previous meta-analyses regarding the effect of L-carnitine supplementation on lipid profiles in patients requiring hemodialysis and people with cardiovascular risk factors, this systematic review and meta- analysis aimed to summarize the effect of L-carnitine on the lipid profiles of patients with liver diseases.

MATERIALS AND METHODS
=====================

Search strategy
---------------

This systematic review and meta-analysis was carried out according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement ([@ref17]). The extensive literature search was carried out in electronic databases, including PubMed, Scopus, Web of Science, and Cochrane library, until April 2019 with no circumscription of language or time. To include patients with liver diseases irrespective of etiology, we searched for the following search terms in the titles, abstracts, and keywords: "hepatic encephalopathy", "liver encephalopathy", "Non-alcoholic Fatty Liver Disease", "Nonalcoholic Steatohepatitis", "Alcoholic Fatty Liver", "Hepatitis", "Human Viral Hepatitides", "Liver Cirrhosis", "Hepatic Cirrhosis", "Liver Fibroses", "Liver Fibrosis", "Liver Neoplasm", "Hepatic Neoplasms", "Cancer of Liver", "Hepatocellular Cancer", and "liver disease" in combination with "levocarnitine", "Vitamin BT", "L-carnitine", "L carnitine", and "carnitine". Moreover, a manual search and reference list check of all the included studies and related reviews was performed to identify further relevant articles.

Study selection
---------------

After deleting duplicate articles, two independent investigators (SK and OA) screened the titles and abstracts of the remaining articles based on the inclusion and exclusion criteria. Articles were eligible for inclusion in this meta-analysis if they fulfilled the following criteria: 1) randomized controlled trials (RCTs) that examined the effects of L-carnitine supplementation on lipid profiles in patients with liver disease; 2) trials with any duration of treatment; 3) reported mean or median values \[with standard deviation (SD), standard error of the mean, or 95% confidence interval (CI)\] at baseline and at the end of the supplementation period in both intervention and control groups. The exclusion criteria were as follows: 1) studies with no placebo or control group; 2) case-control, cross-sectional, cohort design, and review studies; 3) studies which used a combination of other vitamins and minerals; 4) animal studies; 5) studies in which the data was not available.

Data extraction
---------------

The full texts of the selected articles were reviewed to determine whether articles qualified for inclusion. Any disagreements in study inclusion were referred to a third author (AA). The following data was extracted (by RC): first author's name, publication year, study design, participants' characteristics \[sex, age, body mass index (BMI), and disease status\], sample size, duration of intervention, and dose of the supplemented L-carnitine. In addition, we extracted the mean and SD of the blood concentrations of TG, TC, HDL, and LDL at baseline and after intervention.

Quality assessment
------------------

To assess the risk of bias, the Cochrane Collaboration's tool was used ([@ref9]). This tool has nine items, of which each is divided into six domains of bias with three rating categories: 1) low risk of bias (alters the results significantly); 2) unclear risk of bias (raises some doubt about the results); 3) high risk of bias (seriously weakens confidence in the results). All selected articles were scored by 2 authors (SK and RC). Disagreement between the authors was resolved by a third assessor (AA).

Statistical analysis
--------------------

For statistical analysis, we used the mean change and SD of the variables between baseline and post intervention for both the intervention and control groups. Reported standard error (SE) was converted to SD using the following formula: SE×√n. A random effects model was used to calculate the pooled effect size for concentrations of TG, TC, HDL, and LDL. To estimate the impact of each trial on the pooled effect size, sensitivity analysis (metaninf analysis) was performed \[one-study remove (leave-one-out) approach\]. Between-study heterogeneity was examined using Q tests and I-square (I^2^) tests. To calculate the potential sources of between-study heterogeneity, we carried out a pre-planned subgroup analysis based on the dose of L-carnitine, study duration, and type of liver disease. To evaluate publication bias, we used Egger's regression asymmetry test. Statistical analysis was performed using Stata software (version 11.2, StataCorp, College Station, TX, USA) and *P*-values\<0.05 were considered statistically significant.

RESULTS
=======

Literature search
-----------------

The first search yielded 3,227 results. After duplicates were removed, 1,981 articles remained. The titles and abstracts were then screened based on inclusion and exclusion criteria and 1,968 studies were excluded due to the following: 915 were animal studies, 346 were review studies, and 707 did not report relevant studies. Therefore, the full texts of 13 studies were assessed for eligibility, of which 6 studies were considered eligible for inclusion in our meta-analysis ([@ref20]; [@ref25]; [@ref18]; [@ref10]; [@ref6]; [@ref2]). The process of study selection is shown in the flow diagram in [Fig. 1](#F1){ref-type="fig"}.

Study characteristics
---------------------

Pooled data included a total of 234 participants in the intervention arm and 234 participants in the control arm. These studies were all carried out between 2002 and 2016. The overall age range of the participants was 47.8 ∼60 years old, and BMI of the participants ranged between 25.7 and 29.5 kg/m^2^. Durations of intervention ranged from 12 weeks to 48 weeks. The selected studies were conducted in three countries: Italy ([@ref20]; [@ref25]; [@ref18]), South Korea ([@ref10]; [@ref6]), and Iran ([@ref2]). The dose of supplemented L-carnitine ranged from 900 mg to 2,472 mg. The studies included patients with chronic hepatitis C ([@ref20]; [@ref25]) and nonalcoholic fatty liver disease/steatohepatitis (NAFLD/ NASH) ([@ref18]; [@ref10]; [@ref6]; [@ref2]) ([Table 1](#T1){ref-type="table"}).

Assessment of risk of bias
--------------------------

The RCTs risk of bias is shown in [Table 2](#T2){ref-type="table"}. Overall, the assessors agreed on 34 of the 42 items, resulting in an 81% agreement rate. After discussions with the consulting third assessor (AA), 100% agreement was reached. Two studies ([@ref25]; [@ref18]) had the lowest risk of bias and reached the highest score (6 out of 7). Overall, all the studies had a low risk of bias and reached a score of ≥4 out of 7. In all the selected studies, participants were randomization; however, in two studies, participants and study personnel were not blinded ([@ref20]; [@ref25]). Further details are shown in the [Table 2](#T2){ref-type="table"}.

Effect of L-carnitine supplementation on TC levels
--------------------------------------------------

The effect of L-carnitine supplementation on TC levels were examined in four trials with five effect sizes ([@ref2]; [@ref18]; [@ref25]; [@ref20]). Results of the meta- analysis indicated that L-carnitine supplementation reduces blood concentrations of TC \[weighted mean difference and 95% CI: −0.49 mmol/L, (−0.80, −0.17)\] ([Fig. 2](#F2){ref-type="fig"}). The results of the subgroup analysis showed that L- carnitine was effective in reducing TC levels in trials with durations of more than 24 weeks, at doses of less than 2,000 mg/d, and in patients with chronic hepatitis C. The heterogeneity only disappeared in the chronic hepatitis C subgroup ([Table 3](#T3){ref-type="table"}).

Effect of L-carnitine supplementation on TG levels
--------------------------------------------------

Six clinical trials with seven effect sizes evaluated the effect of L-carnitine supplementation on TG levels ([@ref20]; [@ref25]; [@ref18]; [@ref10]; [@ref6]; [@ref2]). The results indicated that L-carnitine supplementation significantly decreased concentrations of TG \[−0.23 mmol/L, (−0.41, −0.05)\] ([Fig. 3](#F3){ref-type="fig"}). Subgroup analysis indicated that L-carnitine was effective in reducing TG when supplemented for 24 weeks, at dose of less than 2,000 mg/d, and in patients with chronic hepatitis C ([Table 3](#T3){ref-type="table"}).

Effect of L-carnitine supplementation on HDL levels
---------------------------------------------------

The effect of the L-carnitine supplementation on HDL levels was examined in 5 clinical trials with 6 effect sizes ([@ref20]; [@ref25]; [@ref18]; [@ref10]; [@ref6]). L-carnitine supplementation had no significant effect on concentrations of HDL \[0.08 mmol/L, (−0.01, 0.18)\] ([Fig. 4](#F4){ref-type="fig"}). Subgroup analysis based on L-carnitine dose, trials duration and type of liver disease indicated that L- carnitine does not affect HDL levels in any of these subgroups ([Table 3](#T3){ref-type="table"}).

Effect of L-carnitine supplementation on LDL levels
---------------------------------------------------

The effect of the L-carnitine supplementation on LDL levels was examined in 5 clinical trials with 6 effect sizes ([@ref20]; [@ref25]; [@ref18]; [@ref10]; [@ref6]). Overall, the meta-analysis did not show any beneficial effect of L-carnitine supplementation on concentrations of LDL \[−0.20 mmol/L, (−0.58, 0.17)\] ([Fig. 5](#F5){ref-type="fig"}). Furthermore, subgroup analysis did not find any beneficial effect of L-carnitine supplementation on LDL ([Table 3](#T3){ref-type="table"}).

Sensitivity analysis and publication bias
-----------------------------------------

We next tested the robustness of our findings through sensitivity analysis. These results demonstrated that overall estimates were not affected by elimination of any one study. Egger's test was conducted to assess publication bias. There was no evidence of publication bias for any studies examining the effect of L-carnitine supplementation on levels of TC (*P*=0.283), HDL (*P*=0.077), and LDL (*P*=0.821); however, there was evidence of publication bias for studies examining the effect of L-carnitine supplementation on levels of TG (*P*=0.024).

DISCUSSION
==========

This systematic review and meta-analysis indicated that L-carnitine supplementation significantly reduces blood levels of TC and TG in patients with liver disease, but is not effective in reducing levels of HDL or LDL. The reducing effect of L-carnitine on levels of both TC and TG was shown following long-term supplementation (≥24 weeks), with doses less than or equal to 2,000 mg/d, and in patients with chronic hepatitis C.

L-Carnitine plays an important role in the metabolism of lipids ([@ref8]). L-Carnitine is implicated in beta oxidation of fatty acids and reduces conversion of free fatty acids to triglycerides ([@ref8]). Several studies have shown that supplementation with L-carnitine and its analogues acetyl and propionyl L-carnitine are effective in regulating plasma concentrations of carnitine, cholesterol, and triglyceride in rats ([@ref14]). A further investigation has shown that carnitine administration could prevent development of atherosclerotic lesions in hypercholesterolemic rabbits ([@ref26]). Recently, a large number of RCTs have evaluated the effect of L-carnitine supplementation on lipid profile in various diseases, however, the results are inconsistent. In 2016, [@ref2] reported that L-carnitine supplementation has no significant effect on serum levels of cholesterol and TG. However, another study indicated that patients treated with L-carnitine showed significant improvements in serum concentrations of TC, LDL, HDL, and TG ([@ref18]).

Liver is the central organ for distributing and metabolizing carnitine. Therefore, any liver disorders can affect carnitine metabolism ([@ref15]). Previous studies have shown that patients with liver disease have lower blood concentrations of carnitine ([@ref27]). The results of our meta-analysis show that L-carnitine supplementation is effective for reducing levels of both TC and TG in patients with liver disease. The beneficial effects of L-carnitine supplementation on improving lipid profiles can be explained through several mechanisms. It is well known that carnitine has an important role in mitochondrial oxidation of long-chain fatty acids. One of the most important steps in fatty acid oxidation is conversion of fatty acyl-CoA to acylcarnitine by carnitine palmitoyl transferase (CPT)-I ([@ref11]). Subsequently, acylcarnitine is transported across the mitochondrial inner membrane. In the matrix, CPT-II transfers the acyl group to CoA, which results in release of carnitine. Then, acyl-CoA enters the fatty acid-oxidation pathway ([@ref11]). Therefore, L-carnitine can reduce conversion of free fatty acids to triglycerides through its role in fatty acid oxidation ([@ref8]). In addition, it has been reported that L-carnitine can affect cholesterol metabolism through inhibition of b-hydroxy b-methylglutaryl (HMG)-CoA reductase activity, which is involved in cholesterol synthesis ([@ref22]). However, we didn't show a beneficial effects of L-carnitine supplementation on reducing LDL levels in patients with liver disease. Although, the beneficial effect of L-carnitine on inhibiting the activity of HMG-CoA reductase has been shown in several studies, other studies report that L-carnitine does not significantly affect LDL receptors. A recent animal study reported that administration of L-carnitine significantly decreases HMG-CoA reductase, but has no significant effect on expression of LDL receptors ([@ref30]). Therefore, the results of our study showing the effect of L-carnitine supplementation on LDL concentrations could be explained through this mechanism.

Previous meta-analyses exploring the effect of L-carnitine supplementation on lipid profiles are contradictory. In 2002, a meta-analysis that included trials conducted on patients undergoing hemodialysis did not show any statistically significant differences in the serum levels of TC, any of its fractions, or TG following L-carnitine supplementation ([@ref13]). Another meta-analysis demonstrated that L-carnitine supplementation is not associated with significant reductions in serum concentrations of TC, HDL, very LDL, and TG, but can significantly reduce LDL levels in patients undergoing hemodialysis ([@ref12]). Moreover, a recent meta- analysis that included trials conducted on participants with cardiovascular risk factors implied that L-carnitine supplementation significantly reduces levels of TC, LDL, and HDL, but not TG. The reasons for these discrepancy between the results of our meta-analysis and the other meta-analyses might partly be due to difference between the included subjects, or another possible mechanisms that is not fully understood. Further studies will reveal more explanations.

According to our findings, L-carnitine is effective in reducing levels of both TC and TG in patients with chronic hepatitis C. One therapeutic option with a proven efficacy for treatment of chronic hepatitis C is IFNα plus ribavirin ([@ref16]). These drugs have immunomodulating and antiviral actions, and can influence the metabolism of lipids ([@ref19]). It has been reported that treatment with IFNα decreases serum HDL levels, increases triglyceride levels and, subsequently, increases the amount of fat in the liver ([@ref23]). Previous investigations have indicated that prolonged treatment with IFNα plus ribavirin results in better response in patients with chronic hepatitis C ([@ref16]). However, it has been shown that liver steatosis and progression of fibrosis reduces the effectiveness of specific antiviral therapies in these patients ([@ref16]). Therefore, carnitine supplementation can be considered as an adjunct therapy for improving antiviral therapies.

Our results did not support the beneficial effect of L- carnitine in patients with NAFLD/NASH. Of four RCTs included in this meta-analysis that assessed the effect of L-carnitine supplementation in patients with NAFLD/ NASH, three studies reported that L-carnitine does not significantly affect lipid profile ([@ref10]; [@ref6]; [@ref2]). The durations of L-carnitine supplementation in all of these studies were less than 24 weeks. Our results indicated that L-carnitine was effective when supplemented for more than 24 weeks. Therefore, one reason for the discrepancy in results regarding the effect of L-carnitine in NAFLD/NASH patients could be the shorter durations of supplementation in these studies. However, further studies should reveal further explanations.

Furthermore, we showed that L-carnitine has a beneficial effect on long-term supplementation. Our results are in line with the previous meta-analysis conducted by [@ref13], which indicated that long-term supplementation of L-carnitine is effective for improving lipid profile of patients undergoing hemodialysis (more than 16 weeks). However, another meta-analysis indicated that both long-term and short-term supplementation of L-carnitine is effective in improving lipid profiles and that long-term supplementation has beneficial effects on glycemia ([@ref5]). Moreover, our results indicated that at doses of less than or equal to 2,000 mg, L- carnitine is effective in reducing levels of both TC and TG. It should be noted that in the studies that administered higher doses of L-carnitine, the trial duration was 12 weeks ([@ref6]; [@ref2]). It can be speculated that the reason for the lack of significant effects of high doses of L-carnitine in these studies might be the short durations of intervention.

Our systematic review and meta-analysis had several strengths. First, this is the first meta-analysis to assess the effect of L-carnitine supplementation on lipid profiles in patients with liver disease. Second, we included RCTs that examined complementary endpoints, providing a comprehensive review of this topic. Third, this review is based on an up-to-date literature search from a large number of databases. An important limitation of this meta-analysis is the low number of trials included, which limits the strength of the conclusions drawn; however, we hope malathis study will be helpful for future studies.

In conclusion, our systematic review and meta-analysis indicated beneficial effect of L-carnitine on levels of TC and TG in patients with liver disease, particularly chronic hepatitis C. These results should be useful information for clinical practice. The combination of L-carnitine with immunomodulatory and antiviral agents in patients with chronic hepatitis C seemed to be more efficacious than these agents alone, and improved the dyslipidemia associated with these drugs. Moreover, this systematic review supports the beneficial effects of L-carnitine supplementation when at doses lower than or equal to 2,000 mg/d, and during long-term supplementation (more than 24 weeks). However, it should be noted that these results are not conclusive and further well-designed studies are required.
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###### 

Characteristic of the studies included in the meta-analysis

  References   Country   Study design   Participants                                                                      Sex   Mean age (intervention/control)   Mean BMI (intervention/control)   Trial duration (week)   Daily dose of L-carnitine (mg)   Daily dose of L-carnitine (mg)
  ------------ --------- -------------- --------------------------------------------------------------------------------- ----- --------------------------------- --------------------------------- ----------------------- -------------------------------- --------------------------------
  [@ref20]     Italy     R              Patients with chronic hepatitis C                                                 F/M   56.8±7.2/ 57.7±6.1                NR/NR                             24                      \>2,000                          35/35
  [@ref25]     Italy     R              Patients with chronic hepatitis C                                                 F/M   50.1±6.1/ 50.4±5.6                25.8/25.7                         24/48                   \>2,000                          35/35
  [@ref18]     Italy     R/DB/PC        Patients with nonalcoholic steatohepatitis                                        F/M   47.9±5.4/ 47.8±5.8                26.6/26.5                         24                      \>2,000                          36/38
  [@ref10]     Korea     R/DB/PC        Patients with nonalcoholic fatty liver disease with impaired glucose metabolism   F/M   51.5±9.4/ 52.0±9.6                27.2/27.0                         12                      900                              26/26
  [@ref6]      Korea     R/DB/PC        Patients with fatty liver disease with type 2 diabetes                            F/M   50.6±9.3/ 52.0±9.4                28.2/26.7                         12                      2,472                            39/39
  [@ref2]      Iran      R/DB/PC        Patients with fatty liver disease with type 2 diabetes                            F/M   60±5/59±9                         28.6/29.5                         12                      2250                             28/26

DB, double-blinded; PC, placebo-controlled; R, randomized; NR, not reported; F, female; M, male.

###### 

Quality assessment (Cochrane Collaboration's tool for assessing risk of bias)

  References   Selection bias   Performance bias   Detection bias   Attrition bias   Reporting bias   Other bias   Total     
  ------------ ---------------- ------------------ ---------------- ---------------- ---------------- ------------ --------- -----
  [@ref20]     Low              Low                High             High             Low              Low          Low       5/7
  [@ref25]     Low              Low                High             Low              Low              Low          Low       6/7
  [@ref18]     Low              Low                Low              High             Low              Low          Low       6/7
  [@ref10]     Low              High               Low              High             Low              Low          Unclear   4/7
  [@ref6]      Low              Low                Low              High             High             Low          Low       5/7
  [@ref2]      Low              High               Low              High             Low              Low          Unclear   4/7

###### 

Subgroup analyses of L-carnitine supplementation on lipid profiles

  Variables               No.   WMD (95% CI)           *P* within group   *P* heterogeneity   I^2^
  ----------------------- ----- ---------------------- ------------------ ------------------- -------
  Total cholesterol                                                                           
  Trial duration (week)                                                                       
  \<24                    1     0.18 (−0.20, 0.58)     0.34               \<0.001             −
  ≥24                     4     −0.61 (−0.93, −0.29)   \<0.001            \<0.001             0.955
  L-Carnitine dose (mg)                                                                       
  \>\>2,000               1     0.18 (−0.20, 0.58)     0.34               \<0.001             −
  ≤2,000                  4     −0.61 (−0.93, −0.29)   \<0.001            \<0.001             0.955
  Type of liver disease                                                                       
  NAFLD/NASH              2     −0.49 (−1.81, 0.82)    0.460              \<0.001             0.974
  Chronic hepatitis C     3     −0.44 (−0.51, −0.37)   \<0.001            0.492               0
  Triglycerides                                                                               
  Trial duration (week)                                                                       
  \<24                    3     0.12 (−0.30, 0.54)     0.57               0.104               0.557
  ≥24                     4     −0.37 (−0.47, −0.27)   \<0.001            0.993               0
  L-Carnitine dose (mg)                                                                       
  \>\>2,000               2     −0.07 (−0.28, 0.13)    0.473              0.912               0
  ≤2,000                  5     −0.28 (−0.48, −0.07)   0.008              0.026               0.638
  Type of liver disease                                                                       
  NAFLD/NASH              4     −0.05 (−0.39, 0.28)    0.753              0.007               0.754
  Chronic hepatitis C     3     −0.38 (−0.50, −0.26)   \<0.001            0.96                0
  HDL-cholesterol                                                                             
  Trial duration (week)                                                                       
  \<24                    2     0.00 (−0.04, 0.06)     0.784              0.896               0
  ≥24                     4     0.11 (−0.00, 0.23)     0.053              \<0.001             0.997
  L-Carnitine dose (mg)                                                                       
  \>\>2,000               1     0.00 (−0.05, 0.06)     0.871              −                   −
  ≤2,000                  5     0.09 (−0.00, 0.20)     0.071              \<0.001             0.996
  Type of liver disease                                                                       
  NAFLD/NASH              3     0.043 (−0.02, 0.11)    0.159              0.027               0.723
  Chronic hepatitis C     3     0.13 (−0.11, 0.36)     0.272              \<0.001             0.998
  LDL-cholesterol                                                                             
  Trial duration (week)                                                                       
  \<24                    2     0.06 (−0.11, 0.24)     0.457              0.853               0
  ≥24                     4     −0.32 (−0.80, 0.15)    0.183              \<0.001             0.988
  L-Carnitine dose (mg)                                                                       
  \>\>2,000               1     0.08 (−0.14, 0.30)     0.474              −                   −
  ≤2,000                  5     −0.25 (−0.68, 0.16)    0.234              \<0.001             0.984
  Type of liver disease                                                                       
  NAFLD/NASH              3     −0.35 (−1.27, 0.57)    0.455              \<0.001             0.981
  Chronic hepatitis C     3     −0.05 (−0.31, 0.21)    0.698              \<0.001             0.952

CI, confidence interval; HDL, high-density lipoprotein; LDL, low-density lipoprotein; WMD, weighted mean differences; NAFLD/NASH, nonalcoholic fatty liver disease/steatohepatitis.
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